Bombesin Analogue-Mediated Delivery Preferentially Enhances the Cytotoxicity of a Mitochondria-Disrupting Peptide in Tumor Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yang, Hao ^a   Cai, Huawei ^a   Wan, Lin ^a   Liu, Shan ^a   Li, Shengfu ^a   Cheng, Jingqiu ^a   Lu, Xiaofeng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B28BN[6-14] PEPTIDE; BN[6-14] PEPTIDE; BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; CASPASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN MOTIF; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; PEPTIDES;

EID: 84874358308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057358     Document Type: Article

References (41)

1. Aluri S, Janib SM, Mackay JA, (2009) Environmentally responsive peptides as anticancer drug carriers. Advance of Drug Delivery Reviews 61: 940-952.
2. Chari RV, (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Accounts of Chemical Research 41: 98-107.
3. Hait WN, Hambley TW (2009) Targeted cancer therapeutics. Cancer Research 69: 1263-1267; discussion 1267.
4. Svensen N, Walton JG, Bradley M, (2012) Peptides for cell-selective drug delivery. Trends in Pharmacological Sciences 33: 186-192.
5. Kapoor P, Singh H, Gautam A, Chaudhary K, Kumar R, et al. (2012) TumorHoPe: a database of tumor homing peptides. PloS One 7: e35187.
6. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, et al. (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328: 1031-1035.
7. Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, et al. (2012) Targeted drug delivery and penetration into solid tumors. Medicinal Research Reviews 32: 1078-1091.
8. Sancho V, Di Florio A, Moody TW, Jensen RT, (2011) Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Current Drug Delivery 8: 79-134.
9. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, et al. (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nature Reviews Endocrinology 5: 382-393.
10. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, et al. (2010) 111In-pentetreotide scintigraphy: procedure guidelines for tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging 37: 1441-1448.
11. Modlin IM, Pavel M, Kidd M, Gustafsson BI, (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Alimentary Pharmacology & Therapeutics 31: 169-188.
12. Jensen RT, Battey JF, Spindel ER, Benya RV, (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacological Reviews 60: 1-42.
13. Moody TW, Sun LC, Mantey SA, Pradhan T, Mackey LV, et al. (2006) In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. The Journal of Pharmacology and Experimental Therapeutics 318: 1265-1272.
14. Engel JB, Keller G, Schally AV, Halmos G, Hammann B, et al. (2005) Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. Clinical Cancer Research 11: 2408-2415.
15. Safavy A, Raisch KP, Matusiak D, Bhatnagar S, Helson L, (2006) Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide "scorpion" molecule. Bioconjugate Chemistry 17: 565-570.
16. Gargosky SE, Wallace JC, Upton FM, Ballard FJ, (1987) C-terminal bombesin sequence requirements for binding and effects on protein synthesis in Swiss 3T3 cells. The Biochemical Journal 247: 427-432.
17. Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, et al. (2011) Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. Journal of Nuclear Medicine 52: 1970-1978.
18. Wagh NK, Zhou Z, Ogbomo SM, Shi W, Brusnahan SK, et al. (2012) Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer. Bioconjugate Chemistry 23: 527-537.
19. Chanda N, Kattumuri V, Shukla R, Zambre A, Katti K, et al. (2010) Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proceedings of the National Academy of Sciences of the United States of America 107: 8760-8765.
20. Kroemer G, Galluzzi L, Brenner C, (2007) Mitochondrial membrane permeabilization in cell death. Physiological Reviews 87: 99-163.
21. Yang H, Liu S, Cai H, Wan L, Li S, et al. (2010) Chondroitin Sulfate as a Molecular Portal That Preferentially Mediates the Apoptotic Killing of Tumor Cells by Penetratin-directed Mitochondria-disrupting Peptides. The Journal of Biological Chemistry 285: 25666-25676.
22. Rege K, Patel SJ, Megeed Z, Yarmush ML, (2007) Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Research 67: 6368-6375.
23. Risso A, Braidot E, Sordano MC, Vianello A, Macri F, et al. (2002) BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Molecular and Cellular Biology 22: 1926-1935.
24. Combet C, Blanchet C, Geourjon C, Deleage G, (2000) NPS@: network protein sequence analysis. Trends in Biochemical Sciences. 25: 147-150.
25. Do TN, Rosal RV, Drew L, Raffo AJ, Michl J, et al. (2003) Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene 22: 1431-1444.
26. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C, (1993) A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochemical and Biophysical Research Communications 197: 40-45.
27. Yang H, Wan L, Li X, Cai H, Chen L, et al. (2007) High level expression of His-tagged colicin 5 in E. coli and characterization of its narrow-spectrum bactericidal activity and pore-forming action. Protein Expression and Purification 54: 309-317.
28. Liu Z, Li ZB, Cao Q, Liu S, Wang F, et al. (2009) Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. Journal of Nuclear Medicine 50: 1168-1177.
29. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, et al. (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. Journal of Nuclear Medicine 49: 318-326.
30. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G, (2011) Cell death assays for drug discovery. Nature Reviews Drug Discovery 10: 221-237.
31. Li Q, Dong C, Deng A, Katsumata M, Nakadai A, et al. (2005) Hemolysis of erythrocytes by granulysin-derived peptides but not by granulysin. Antimicrobial Agents and Chemotherapy 49: 388-397.
32. Kwekkeboom DJ, de Herder WW, Krenning EP (2011) Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40: 173-185, ix.
33. Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, et al. (2012) Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. The Prostate 72: 318-325.
34. Weber HC, (2009) Regulation and signaling of human bombesin receptors and their biological effects. Current Opinion in Endocrinology, Diabetes, and Obesity 16: 66-71.
35. Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, et al. (2005) Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clinical Cancer Research 11: 49-57.
36. Hoskin DW, Ramamoorthy A, (2008) Studies on anticancer activities of antimicrobial peptides. Biochimica et Biophysica Acta 1778: 357-375.
37. Harsman A, Niemann M, Pusnik M, Schmidt O, Burmann BM, et al. (2012) Bacterial origin of a mitochondrial outer membrane protein translocase: new perspectives from comparative single channel electrophysiology. The Journal of Biological Chemistry 287: 31437-31445.
38. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
39. Gogvadze V, Orrenius S, Zhivotovsky B, (2009) Mitochondria as targets for chemotherapy. Apoptosis 14: 624-640.
40. Dapp S, Garcia Garayoa E, Maes V, Brans L, Tourwe DA, et al. (2011) PEGylation of (99 m)Tc-labeled bombesin analogues improves their pharmacokinetic properties. Nuclear Medicine and Biology 38: 997-1009.
41. Sawyers CL, (2008) The cancer biomarker problem. Nature 452: 548-552.